Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC.

Patient, Provider, and Caregiver Connection™: Collaborative Approaches to Chronic Kidney Disease Management in T2DM

Access Activity

Overview / Abstract:

Program Overview

This video-based program is designed for health care professionals to explore the available treatments for diabetic kidney disease (DKD) through a unique perspective, putting the patient’s voice front and center. A patient will lend their expertise to this program by sharing their journey living with DKD. This online activity focuses on the complex disease pathophysiology of DKD, the diseases and complications directly related to DKD, and the efficacy and safety of therapies recommended for treating DKD.

Diabetic kidney disease (DKD) is a disease multiplier that increases the risk of stroke and cardiac and vascular disease. Patients with DKD have a high risk of renal and diabetes complications, including diabetic retinopathy, diabetic foot, anemia, metabolic bone disease, fractures, infection, and neuropathy. Not surprisingly, this burden of complications and comorbidities translates to poor quality of life and substantially higher healthcare resource utilization and costs. Effective treatment for DKD is a key unmet need because, although advances in diabetes care have substantially reduced the incidence of most diabetes complications, efforts to reduce progression to end-stage renal disease (ESRD) have stubbornly lagged behind others. There are several classes of glucose-lowering drugs that have shown beneficial renal effects in patients with DKD. These include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and nonsteroidal mineralocorticoid receptor antagonists (MRAs).

Learning Objectives

Upon completion of this activity, participants should be better able to:

Describe recommended diagnostic practices for CKD in patients with type 2 diabetes mellitus (T2DM)
Evaluate the efficacy and safety profiles of available antihyperglycemic agents and their cardiovascular and renal benefits in patients with T2DM
Recognize the complex pathophysiology of CKD and emerging approaches to intervene in disease progression

Expiration

Sep 30, 2022

Discipline(s)

Nursing CNE, Physician CME

Format

Online

Credits / Hours

1.5 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
George Bakris, MD
Professor of Medicine
Director, American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

FACULTY_NAME
Kim Zuber, PAC, MS
Executive Director
American Academy of Nephrology PAs
St Petersburg, FL

Patient

Janice Starling
Patient with CKD

Sponsors / Supporters / Grant Providers

Bayer Healthcare Pharmaceuticals Inc

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Chronic Kidney Disease Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map